VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2020 | IV daratumumab in R/R myeloma: bodyweight analysis

Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, discusses the Phase III COLUMBA (NCT03277105) study evaluating subcutaneous intravenous (IV) daratumumab in relapsed/refractory (R/R) multiple myeloma patients, specifically discussed is the results of the bodyweight subgroup analysis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter